Join Clinical Trials in Connecticut for Cancer

All Categories Most Often Searched » Cancer » Connecticut

An Observational Pilot Study Evaluating The Feasibility of Conducting Genomewide Association Studies Utilizing Subject-Provided Information in Subjects With Metastatic Breast Cancer Treated With Avastin (Bevacizumab)

Condition: Breast Cancer
Intervention:
Sponsors: Genentech; Genentech; 23andMe, Inc.
Recruiting - verified May 2012
A Study of LY2784544 in Participants With Myeloproliferative Neoplasms

Condition: Neoplasms, Hematologic
Interventions: Drug: 200 mg LY2784544; Drug: 400 mg LY2784544; Drug: 600 mg LY2784544
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Not yet recruiting - verified May 2012
Head to Head Study Epi proColon and FIT

Condition: Colorectal Cancer
Intervention:
Sponsors: Epigenomics, Inc; Epigenomics, Inc
Recruiting - verified April 2012
Preventative Trial of DFMO in Patients With High Risk Neuroblastoma in Remission

Condition: Neuroblastoma in Remission
Intervention: Drug: DFMO
Sponsors: Van Andel Research Institute; Giselle Sholler; Cancer Prevention Pharmaceuticals, Inc.; University of Arizona; University of Hawaii Cancer Research Center; University of Vermont
Not yet recruiting - verified April 2012
Cancer Symptom Data From Multiple Treatment Centers

Conditions: Breast Cancer; Colon Cancer
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified November 2011
Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer

Condition: Breast Cancer
Interventions: Drug: AC regimen; Drug: TAC regimen; Drug: cyclophosphamide; Drug: docetaxel; Drug: doxorubicin hydrochloride; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI)
Recruiting - verified May 2012
A Pilot Study of Sorafenib Examining Biomarkers in Refractory or Relapsed T-Cell Lymphoma Patients

Condition: T Cell Lymphoma
Intervention: Drug: Sorafenib
Sponsors: Yale University; Yale University
Recruiting - verified March 2012
Veliparib in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Conditions: brca1 Mutation Carrier; brca2 Mutation Carrier; Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Drug: veliparib; Genetic: DNA analysis; Genetic: polymorphism analysis; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy

Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: erlotinib; Drug: afatinib
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012
Study of Modified FOLFIRINOX in Advanced Pancreatic Cancer

Conditions: Metastatic Pancreatic Cancer; Pancreatic Cancer
Intervention: Drug: Folfirinox
Sponsors: Yale University; Yale University
Recruiting - verified January 2012
Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer

Conditions: Head and Neck Cancer; Kidney Cancer; Liver Cancer; Sarcoma
Interventions: Drug: sorafenib tosylate; Genetic: gene expression analysis; Genetic: mutation analysis; Genetic: polymerase chain reaction; Other: enzyme-linked immunosorbent assay; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Randomized Efficacy Study of TPI 287 to Treat Primary Refractory or Early Relapsed Neuroblastoma

Condition: Neuroblastoma
Interventions: Drug: TPI 287; Drug: Temozolomide; Drug: Irinotecan
Sponsors: Van Andel Research Institute; Giselle Sholler; Archer Biosciences, Inc.
Recruiting - verified April 2012
Combination Chemotherapy in Treating Patients With Advanced or Metastatic Esophageal Cancer, Gastric Cancer, or Gastroesophageal Junction Cancer

Conditions: Adenocarcinoma of the Gastroesophageal Junction; Esophageal Cancer; Gastric Cancer
Interventions: Drug: FOLFOX regimen; Drug: docetaxel; Drug: fluorouracil; Drug: irinotecan hydrochloride; Drug: leucovorin calcium; Drug: oxaliplatin
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Study Evaluating the Safety and Efficacy Of Carboplatin/Paclitaxel And Carboplatin/Paclitaxel/Bevacizumab With and Without GDC-0941 in Patients With Previously Untreated Advanced Or Recurrent Non-small Cell Lung Cancer

Condition: Non-Small Cell Lung Cancer
Interventions: Drug: GDC-0941; Drug: carboplatin; Drug: paclitaxel; Drug: bevacizumab; Drug: Placebo
Sponsors: Genentech; Genentech
Recruiting - verified February 2012
Caris Biorepository Research Protocol

Condition: Cancer
Intervention:
Sponsors: Caris Science, Inc.; Caris Science, Inc.
Recruiting - verified February 2012
A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Patients With Hormone Receptor-Positive, Metastatic HER2-positive Breast Cancer

Condition: Breast Cancer
Interventions: Drug: pertuzumab; Drug: trastuzumab; Drug: Aromatase Inhibitor; Drug: Induction Chemotherapy
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2012
Safety and Efficacy Study of TPI-287 in Neuroblastoma and Medulloblastoma

Conditions: Neuroblastoma; Medulloblastoma
Intervention: Drug: TPI 287
Sponsors: Van Andel Research Institute; Giselle Sholler; Van Andel Research Institute; Archer Biosciences, Inc.
Recruiting - verified April 2012
Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma

Conditions: Glioblastoma; Small Cell Glioblastoma; Giant Cell Glioblastoma; Gliosarcoma; Glioblastoma With Oligodendroglial Component
Interventions: Drug: Rindopepimut (CDX-110) with GM-CSF; Drug: Temozolomide; Drug: KLH
Sponsors: Celldex Therapeutics; Celldex Therapeutics
Recruiting - verified May 2012
A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma

Condition: Pancreatic Cancer
Interventions: Drug: GS-6624; Drug: GS-6624; Drug: Placebo; Drug: Gemcitabine; Drug: Gemcitabine; Drug: Gemcitabine; Drug: Gemcitabine; Drug: GS-6624
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified March 2012
Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Persistent or Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Drug: paclitaxel; Drug: pazopanib hydrochloride; Other: placebo
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Condition: Colorectal Cancer
Interventions: Drug: GS-6624; Drug: FOLFIRI; Drug: GS-6624; Drug: FOLFIRI; Drug: GS-6624; Drug: FOLFIRI; Drug: Placebo; Drug: FOLFIRI
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified March 2012
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma

Condition: Follicular Lymphoma
Interventions: Drug: Rituximab; Drug: Lenalidomide; Drug: Rituximab-CHOP; Drug: Rituximab-CVP; Drug: Rituximab-Bendamustine
Sponsors: Celgene Corporation; Celgene Corporation; Groupe d'Etude des Lymphomes de l'Adulte - Recherche Clinique
Recruiting - verified April 2012
Novel Treatments to Enhance Smoking Cessation Before Cancer Surgery: Effects on Smoking and Surgical Outcomes

Condition: Smoking Cessation
Interventions: Other: standard care; Other: standard care plus contingency management
Sponsors: Yale University; Yale University
Recruiting - verified April 2012
Clinical and Biological Predictors of Chemotherapy Toxicity in Older Adults

Condition: Breast Cancer
Intervention:
Sponsors: City of Hope Medical Center; City of Hope Medical Center; National Institutes of Health (NIH); National Institute on Aging (NIA)
Recruiting - verified November 2011
Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma

Condition: Multiple Myeloma
Interventions: Biological: Elotuzumab; Drug: Bortezomib; Drug: Dexamethasone; Drug: Dexamethasone; Drug: Dexamethasone; Drug: Dexamethasone
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Abbott Biotherapeutics Corp.
Recruiting - verified February 2012
Reversing Hormone Resistance in Advanced Breast Cancer With Pazopanib

Conditions: Breast Cancer; Breast Neoplasm
Intervention: Drug: Pazopanib
Sponsors: University of California, San Francisco; Hope Rugo, MD; GlaxoSmithKline
Recruiting - verified April 2012
Alisertib in Treating Patients With Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma

Condition: Lymphoma
Interventions: Drug: alisertib; Genetic: fluorescence in situ hybridization; Genetic: microarray analysis; Genetic: mutation analysis; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Lenalidomide Intensification in Patients With Serologic/Asymptomatic Progression of Multiple Myeloma While on Lenalidomide Maintenance After Autologous Stem Cell Transplantation

Condition: Multiple Myeloma
Intervention: Drug: lenalidomide
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Montefiore Medical Center; State University of New York - Downstate Medical Center; NYU MEDICAL CENTER; University of Rochester; Weill Medical College of Cornell University; Stamford Hospital
Recruiting - verified March 2012
Maintenance Therapy: Lenalidomide Following Bendamustine and Rituximab Induction Therapy for Chronic Lymphocytic Leukemia

Condition: Chronic Lymphocytic Leukemia
Intervention: Drug: Maintenance lenalidomide
Sponsors: Yale University; Yale University; Celgene Corporation
Recruiting - verified March 2012
Pediatric Philadelphia Positive Acute Lymphoblastic Leukemia

Condition: Leukemia, Pediatric
Intervention: Drug: Dasatinib
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Children's Oncology Group; EsPhALL - European Intergroup Study on Post Induction Treatment of Philadelphia Positive Acute Lymphoblastic Leukaemia with Imatinib
Recruiting - verified April 2012
A Study of GDC-0980 in the Treatment of Recurrent or Persistent Endometrial Carcinoma

Condition: Endometrial Carcinoma
Intervention: Drug: GDC-0980
Sponsors: Genentech; Genentech
Recruiting - verified October 2011
A Phase I/IIa, First Time in Human, Study of GSK2636771 in Subjects With Advanced Solid Tumors With Phosphatase and Tensin Homolog (PTEN) Deficiency

Condition: Cancer
Intervention: Drug: GSK2636771
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2012
A Study Comparing Siltuximab Plus Best Supportive Care to Placebo Plus Best Supportive Care in Anemic Patients With International Prognostic Scoring System Low- or Intermediate-1-Risk Myelodysplastic Syndrome

Condition: Myelodysplastic Syndrome
Interventions: Drug: Siltuximab + BSC; Drug: Placebo + BSC
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified April 2012
Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile

Condition: Multiple Myeloma
Intervention:
Sponsors: Multiple Myeloma Research Foundation; Multiple Myeloma Research Foundation; Translational Genomics Research Institute, Phoenix, Arizona.; Spectrum Health Hospitals; Van Andel Research Institute; Quintiles
Recruiting - verified May 2012
A Phase 1/2 Study of the Oral ALK/EGFR Inhibitor AP26113

Conditions: Advanced Malignancies; Carcinoma, Non-Small-Cell Lung; Anaplastic Large Cell Lymphoma; Diffuse Large Cell Lymphoma; Inflammatory Myofibroblastic Tumors
Intervention: Drug: AP26113
Sponsors: Ariad Pharmaceuticals; Ariad Pharmaceuticals
Recruiting - verified April 2012
A Randomized Controlled Trial of Routine Shave Margins Versus Standard Partial Mastectomy in Breast Cancer Patients

Condition: Breast Cancer
Interventions: Procedure: Shave margins; Procedure: No Shave Margins
Sponsors: Yale University; Yale University
Recruiting - verified November 2011
Biomarker Study of Elotuzumab in High Risk Smoldering Myeloma

Condition: Smoldering Multiple Myeloma
Intervention: Biological: Elotuzumab (BMS-901608; HuLuc63)
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Abbott Biotherapeutics Corp.
Recruiting - verified February 2012
Multi-arm Study of BMS-936558 in Combination With 3 Platinum-based Doublet Chemotherapy Regimens in Subjects With Treatment-Naive Stage IIIB/IV Non-small Cell Lung Cancer

Condition: Non-small Cell Lung Cancer
Interventions: Drug: BMS-936558 (Anti-PD1); Drug: BMS-936558 (Anti-PD1); Drug: BMS-936558 (Anti-PD1); Drug: Gemcitabine; Drug: Cisplatin; Drug: Pemetrexed; Drug: Paclitaxel; Drug: Carboplatin
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Ono Pharma
Recruiting - verified February 2012
A Study of Ramucirumab (IMC-1121B) in Combination With Eribulin Versus Eribulin Alone in Patients With Breast Cancer

Condition: Breast Cancer
Interventions: Biological: Ramucirumab (IMC-1121B); Drug: Eribulin
Sponsors: ImClone LLC; ImClone LLC
Recruiting - verified May 2012
Safety, Tolerability and Efficacy Study of the Monoclonal Antibody, CT-011, in Patients With Metastatic Melanoma

Conditions: Melanoma; Malignant Melanoma
Intervention: Drug: CT-011
Sponsors: CureTech Ltd; CureTech Ltd
Recruiting - verified January 2012
Study of Ruxolitinib in Pancreatic Cancer Patients

Condition: Metastatic Pancreatic Adenocarcinoma
Interventions: Drug: Number 1 - Capecitabine and ruxolitinib; Drug: Number 2 - Capecitabine and placebo
Sponsors: Incyte Corporation; Incyte Corporation
Recruiting - verified May 2012
A Study of Trastuzumab Emtansine in Comparison With Treatment of Physician's Choice in Patients With HER2-Positive Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-Directed Therapy (TH3RESA)

Condition: Breast Cancer
Interventions: Drug: trastuzumab emtansine; Drug: anti-cancer therapy
Sponsors: Genentech; Genentech
Recruiting - verified March 2012
Efficacy and Safety of Multi-Instillations of Apaziquone in Patients With Non-Muscle Invasive Bladder Cancer

Condition: Bladder Cancer
Interventions: Drug: Apaziquone; Drug: Placebo
Sponsors: Spectrum Pharmaceuticals, Inc; Spectrum Pharmaceuticals, Inc; Allergan
Recruiting - verified April 2012
A Study of RO5072759 (GA101) in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER)

Condition: Lymphoma, B-Cell
Interventions: Drug: RO50722759; Drug: cyclophosphamide; Drug: doxorubicin; Drug: vincristine; Drug: prednisone
Sponsors: Genentech; Genentech
Recruiting - verified May 2012
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia

Conditions: Cognitive/Functional Effects; Leukemia; Neurotoxicity; Pain; Therapy-related Toxicity
Interventions: Drug: clofarabine; Drug: cyclophosphamide; Drug: cytarabine; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: hydrocortisone sodium succinate; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: pegaspargase; Drug: prednisone; Drug: thioguanine; Drug: vincristine sulfate; Radiation: selective external radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer

Conditions: Colorectal Neoplasms; Digestive System Diseases; Colonic Diseases; Colorectal Cancer
Intervention:
Sponsors: Exact Sciences Corporation; Exact Sciences Corporation
Recruiting - verified August 2011
pCLE For the Diagnosis Of Cancer in Unknown Bile Duct Stricture

Conditions: Cholangiocarcinoma; Bile Duct Inflammation
Intervention:
Sponsors: Mauna Kea Technologies; Mauna Kea Technologies
Recruiting - verified May 2012
A Study of LY2510924 and Sunitinib in Patients With Metastatic Renal Cell Carcinoma

Condition: Metastatic Clear Cell Renal Cell Carcinoma
Interventions: Drug: LY2510924; Drug: Sunitinib
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified April 2012
Erlotinib Plus ARQ 197 Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Condition: Metastatic Non-Small Cell Lung Cancer
Interventions: Drug: ARQ 197 plus erlotinib; Drug: Pemetrexed, docetaxel or gemcitabine
Sponsors: ArQule; ArQule
Recruiting - verified January 2012
Omega-3-Fatty Acid Supplements in Treating Muscle and Bone Pain and Stiffness in Patients With Stage I, Stage II, or Stage III Breast Cancer Receiving Hormone Therapy

Conditions: Arthralgia; Breast Cancer; Pain
Interventions: Dietary Supplement: omega-3 fatty acid; Other: placebo
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Prasterone (Dehydroepiandrosterone) in Treating Postmenopausal Cancer Survivors With Vaginal Symptoms

Condition: Cancer
Interventions: Drug: prasterone; Other: placebo
Sponsors: National Cancer Institute (NCI); North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified February 2012
Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer

Condition: Colorectal Cancer
Interventions: Drug: bevacizumab; Drug: FOLFIRI regimen; Drug: mFOLFOX6
Sponsors: Genentech; Genentech
Recruiting - verified December 2011
Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer

Condition: Prostate Cancer
Interventions: Radiation: radiation therapy; Radiation: selective external radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Chemotherapy Toxicity On Quality of Life in Older Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Biological: filgrastim; Drug: carboplatin; Drug: paclitaxel; Other: pharmacological study; Other: questionnaire administration; Procedure: assessment of therapy complications; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group
Recruiting - verified May 2012
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Conditions: Crohn's Disease; IBD; Colitis; Inflammatory Bowel Disease
Interventions: Drug: Group 2 ustekinumab 130 mg; Drug: Group 3: ustekinumab approximately 6 mg/kg; Drug: Group 1: Placebo
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified April 2012
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer

Condition: Non Small Cell Lung Cancer
Interventions: Drug: IPI 504 plus Docetaxel; Drug: Placebo plus Docetaxel
Sponsors: Infinity Pharmaceuticals, Inc.; Infinity Pharmaceuticals, Inc.
Recruiting - verified February 2012
Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in Uterine Serous Cancer

Condition: Endometrial Cancer
Interventions: Drug: Carboplatin/Paclitaxel; Drug: Trastuzumab
Sponsors: Yale University; Yale University; Genentech
Recruiting - verified January 2012
Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer

Condition: Metastatic Pancreatic Adenocarcinoma
Interventions: Drug: ON 01910.Na; Drug: Gemcitabine; Drug: Gemcitabine
Sponsors: Onconova Therapeutics, Inc.; Onconova Therapeutics, Inc.; Academic Oncology Gastrointestinal Cancer Consortium (AGICC)
Recruiting - verified March 2012
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

Condition: Breast Cancer
Interventions: Drug: pertuzumab; Drug: placebo; Drug: trastuzumab [Herceptin]; Drug: Chemotherapy
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche; Breast International Group; Genentech
Recruiting - verified February 2012
Phase I Biomarker Study (BMS-936558)

Condition: Renal Cell Carcinoma
Interventions: Drug: BMS-936558 (Anti-PD-1); Drug: BMS-936558 (Anti-PD-1); Drug: BMS-936558 (Anti-PD-1)
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Ono Pharma
Recruiting - verified February 2012
PET-Directed Therapy in Treating Patients With Limited-Stage Diffuse Large B-Cell Lymphoma

Condition: Lymphoma
Interventions: Biological: rituximab; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: prednisone; Drug: vincristine sulfate; Other: R-CHOP regimen; Other: laboratory biomarker analysis; Radiation: fludeoxyglucose F 18; Radiation: selective external radiation therapy; Radiation: yttrium Y 90 ibritumomab tiuxetan
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
A Study of Avastin (Bevacizumab) in Combination With Standard of Care Treatment in Patients With Lung Cancer

Condition: Non-Small Cell Lung Cancer
Interventions: Drug: bevacizumab [Avastin]; Drug: Standard of care treatment
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2012
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

Conditions: Hematological Malignancies; Certain Lysosomal Storage and Peroxisomal Enzyme Deficiency Disorders; Hurler Syndrome (MPS I); Krabbe Disease (Globoid Leukodystrophy); X-linked Adrenoleukodystrophy; Primary Immunodeficiency Diseases; Bone Marrow Failure; Beta-thalassemia
Intervention: Drug: A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs)
Sponsors: Center for International Blood and Marrow Transplant Research; Center for International Blood and Marrow Transplant Research; National Marrow Donor Program
Recruiting - verified April 2012
Molecular Guided Therapy for Refractory or Recurrent Neuroblastoma

Condition: Neuroblastoma
Intervention: Device: Guided Therapy
Sponsors: Van Andel Research Institute; Giselle Sholler
Recruiting - verified April 2012
A Study of Trabectedin or Dacarbazine for the Treatment of Patients With Advanced Liposarcoma or Leiomyosarcoma

Condition: Advanced Liposarcoma or Leiomyosarcoma
Interventions: Drug: Trabectedin; Drug: Dacarbazine
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC; Pharma Mar, S.A.U.
Recruiting - verified May 2012
ARCHER 1009 : A Study Of PF-00299804 (Dacomitinib) Vs. Erlotinib In The Treatment Of Advanced Non-Small Cell Lung Cancer

Condition: Non-Small Cell Lung Cancer (NSCLC)
Interventions: Drug: Dacomitinib (PF-00299804); Drug: Active Comparator (erlotinib)
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide; Drug: Dexamethasone; Drug: Dexamethasone; Drug: Dexamethasone; Drug: Dexamethasone; Biological: Elotuzumab (BMS-901608; HuLuc63); Biological: Elotuzumab (BMS-901608; HuLuc63)
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Abbott Biotherapeutics Corp.
Recruiting - verified October 2011
Study of Ombrabulin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer Treated With Carboplatin/Paclitaxel

Condition: Ovarian Cancer Recurrent
Interventions: Drug: Ombrabulin (AVE8062); Drug: Placebo; Drug: Paclitaxel; Drug: Carboplatin
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified May 2012
A Phase II Study of Efficacy and Safety in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma

Condition: Basal Cell Carcinoma
Intervention: Drug: LDE225
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant

Conditions: Diffuse Large B-cell Lymphoma; de Novo DLBCL; DLBCL Transformed From Indolent Lymphoma; Follicular Grade 3 Lymphoma
Interventions: Drug: Pixantrone + Rituximab; Drug: Gemcitabine + Rituximab
Sponsors: Cell Therapeutics; Cell Therapeutics
Recruiting - verified May 2012
SOM 230 and Everolimus in Combination for the Treatment of Prostate Cancer

Conditions: Castrate Resistant Prostate Cancer; Chemotherapy Naive Prostate Cancer; Prostate Cancer
Interventions: Drug: Pasireotide; Drug: Combination treatment with SOM230 and Everolimus
Sponsors: Thomas Jefferson University; Thomas Jefferson University; Novartis Pharmaceuticals
Recruiting - verified January 2012
Continuous Versus Intermittent Dosing Regimens for Pomalidomide in Relapsed/Refractory Multiple Myeloma

Condition: Multiple Myeloma
Intervention: Drug: Pomalidomide
Sponsors: Yale University; Yale University; Celgene Corporation
Recruiting - verified July 2011
Abiraterone Acetate in Treating Patients With Prostate Cancer Who Have Undergone Initial Hormone Therapy

Condition: Prostate Cancer
Interventions: Drug: abiraterone acetate; Drug: degarelix; Drug: goserelin acetate; Drug: leuprolide acetate; Procedure: orchiectomy
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2012
Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: Cabazitaxel (XRP6258); Drug: Docetaxel (XRP6976); Drug: Prednisone
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified April 2012
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: Cabazitaxel (XRP6258); Drug: Prednisone
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified May 2012
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer

Conditions: Advanced Prostate Cancer; Prostatic Neoplasms
Intervention: Biological: sipuleucel-T
Sponsors: Dendreon; Dendreon
Recruiting - verified March 2012
Bevacizumab With or Without Fosbretabulin Tromethamine in Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Biological: bevacizumab; Drug: fosbretabulin tromethamine
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Radiation Therapy With Cisplatin or Cetuximab in Treating Patients With Oropharyngeal Cancer

Conditions: Head and Neck Cancer; Precancerous Condition
Interventions: Biological: cetuximab; Drug: cisplatin
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Caspofungin Acetate or Fluconazole in Preventing Invasive Fungal Infections in Patients With Acute Myeloid Leukemia Who Are Undergoing Chemotherapy

Conditions: Fungal Infection; Leukemia; Neutropenia
Interventions: Drug: caspofungin acetate; Drug: fluconazole
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
A Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia

Condition: Acute Myeloid Leukemia
Interventions: Drug: Sapacitabine and decitabine; Drug: Decitabine
Sponsors: Cyclacel Pharmaceuticals, Inc.; Cyclacel Pharmaceuticals, Inc.
Recruiting - verified November 2011
A Study of GA101 (RO5072759) in Combination With Chemotherapy in Patients With Previously Untreated Chronic Lymphocytic Leukemia (GALTON)

Condition: Chronic Lymphocytic Leukemia
Interventions: Drug: bendamustine; Drug: cyclophosphamide; Drug: Fludarabine; Drug: RO5072759
Sponsors: Genentech; Genentech
Recruiting - verified March 2012
A Study of MDV3100 Versus Bicalutamide in Castrate Men With Metastatic Prostate Cancer

Condition: Prostatic Neoplasms
Interventions: Drug: MDV3100; Drug: Bicalutamide
Sponsors: Astellas Pharma Inc; Astellas Pharma Inc; Medivation, Inc.
Recruiting - verified March 2012
A Study of RO5185426 (Vemurafenib) in Patients With Metastatic or Unresectable Papillary Thyroid Cancer Positive for the BRAF V600 Mutation

Condition: Neoplasms
Intervention: Drug: RO5185426
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2012
Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Plus Paclitaxel and Carboplatin Versus Placebo Plus Paclitaxel and Carboplatin

Condition: Lung Cancer - Non Small Cell
Interventions: Drug: Ipilimumab; Drug: Placebo; Drug: Paclitaxel; Drug: Carboplatin
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified April 2012
Combination Chemotherapy Plus Bevacizumab With or Without Oxaliplatin in Treating Older Patients With Metastatic Colorectal Cancer

Conditions: Cognitive/Functional Effects; Colorectal Cancer; Neurotoxicity
Interventions: Biological: bevacizumab; Drug: capecitabine; Drug: fluorouracil; Drug: leucovorin calcium; Drug: oxaliplatin
Sponsors: National Cancer Institute (NCI); North Central Cancer Treatment Group; National Cancer Institute (NCI); Cancer and Leukemia Group B
Recruiting - verified February 2012
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer

Condition: Breast Cancer
Interventions: Biological: trastuzumab; Drug: cyclophosphamide; Drug: docetaxel; Drug: doxorubicin hydrochloride; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI)
Recruiting - verified February 2012
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer

Condition: Breast Cancer
Interventions: Drug: anastrozole; Drug: exemestane; Drug: letrozole; Drug: systemic chemotherapy; Drug: tamoxifen citrate
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2012
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III or Stage IV Melanoma That Has Been Removed by Surgery

Condition: Melanoma (Skin)
Interventions: Biological: ipilimumab; Biological: recombinant interferon alfa-2b
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Brivanib in Treating Patients With Persistent or Recurrent Cervical Cancer

Condition: Cervical Cancer
Interventions: Drug: brivanib alaninate; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Study of ACE-011 to Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer

Conditions: Anemia; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small-Cell Lung; Bladder Cancer; Cancer of Head and Neck; Uterine Cervical Cancer
Interventions: Drug: ACE-011 - 15 mg; Drug: ACE-011 - 30 mg; Drug: ACE-011 - 45 mg
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified February 2012
MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer

Conditions: Adenocarcinoma of the Gastroesophageal Junction; Esophageal Cancer; Gastric Cancer
Intervention: Drug: Akt inhibitor MK2206
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
A Study to Evaluate the Safety and Efficacy of Inactivated Varicella-zoster Vaccine (VZV) as a Preventative Treatment for Herpes Zoster (HZ) and HZ-related Complications in Adult Participants With Solid Tumor or Hematologic Malignancy (V212-011 AM1)

Condition: Herpes Zoster
Interventions: Biological: V212; Biological: Placebo
Sponsors: Merck; Merck
Recruiting - verified May 2012
Ranibizumab as Adjuvant Therapy for the Treatment of Choroidal Melanoma (Cohort 2)

Condition: Choroidal Melanoma
Interventions: Drug: Ranibizumab 2 mg; Drug: 0.5 mg Ranibizumab
Sponsors: New England Retina Associates; New England Retina Associates; Genentech
Recruiting - verified August 2011
Early Surgery or Standard Palliative Therapy in Treating Patients With Stage IV Breast Cancer

Condition: Breast Cancer
Interventions: Procedure: palliative surgery; Procedure: therapeutic conventional surgery; Radiation: palliative radiation therapy; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Diet in Altering Disease Progression in Patients With Prostate Cancer on Active Surveillance

Condition: Prostate Cancer
Interventions: Behavioral: telephone-based intervention; Other: counseling intervention; Other: educational intervention; Procedure: therapeutic dietary intervention
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified February 2012
Colonoscopy Versus Fecal Immunochemical Testing in Reducing Mortality From Colorectal Cancer (CONFIRM)

Condition: Colorectal Cancer
Interventions: Procedure: Colonoscopy; Procedure: FIT
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs
Not yet recruiting - verified April 2012
Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting

Condition: Chronic Myeloid Leukemia
Intervention:
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; ICON Clinical Research
Recruiting - verified May 2012
Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Docetaxel and Prednisone (CRPC)

Condition: Castrate-Resistant Prostate Cancer
Interventions: Drug: ISIS EIF4E Rx; Drug: ISIS EIF4E Rx; Drug: ISIS EIF4E Rx; Drug: Prednisone; Drug: Docetaxel
Sponsors: Isis Pharmaceuticals; Isis Pharmaceuticals
Recruiting - verified April 2012
Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma

Conditions: Brain and Central Nervous System Tumors; Kidney Cancer; Sarcoma
Interventions: Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: ifosfamide; Drug: topotecan hydrochloride; Drug: vincristine sulfate
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Everolimus and Octreotide With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed By Surgery

Conditions: Islet Cell Tumor; Pancreatic Cancer
Interventions: Biological: bevacizumab; Drug: everolimus; Drug: octreotide acetate
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified May 2012
Randomized Study of ON 01910.Na in Refractory Myelodysplastic Syndrome Patients With Excess Blasts

Conditions: Myelodysplastic Syndromes; MDS; RAEB; Chronic Myelomonocytic Leukemia
Intervention: Drug: ON 01910.Na
Sponsors: Onconova Therapeutics, Inc.; Onconova Therapeutics, Inc.; The Leukemia and Lymphoma Society
Recruiting - verified April 2012
BIBF 1120 in Treating Patients With Recurrent or Persistent Endometrial Cancer

Condition: Endometrial Cancer
Intervention: Drug: multitargeted tyrosine kinase inhibitor BIBF 1120
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified April 2012
Vitamin D and Breast Cancer Biomarkers in Female Patients

Condition: Breast Cancer
Interventions: Dietary Supplement: vitamin D; Other: placebo
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified May 2012
Dose Escalation Study of ARQ 736 in Adult Subjects With Advanced Solid Tumors Harboring BRAF and/or NRAS Mutations

Condition: Solid Tumor
Intervention: Drug: ARQ 736
Sponsors: ArQule; ArQule
Recruiting - verified October 2011
Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Malignant Salivary Gland Tumors That Have Been Removed By Surgery

Condition: Head and Neck Cancer
Interventions: Drug: cisplatin; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Study of Abiraterone Acetate in Patients With Advanced Prostate Cancer

Conditions: Prostate Neoplasms; Genital Neoplasms, Male; Urogenital Neoplasms; Genital Diseases, Male
Intervention: Drug: Abiraterone Acetate
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Available - verified April 2012
Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors

Condition: Brain and Central Nervous System Tumors
Interventions: Biological: bevacizumab; Drug: irinotecan hydrochloride; Drug: temozolomide
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Vinorelbine Ditartrate and Cyclophosphamide in Combination With Bevacizumab or Temsirolimus in Treating Patients With Recurrent or Refractory Rhabdomyosarcoma

Condition: Sarcoma
Interventions: Biological: bevacizumab; Drug: cyclophosphamide; Drug: temsirolimus; Drug: vinorelbine tartrate
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy

Condition: Sarcoma
Interventions: Drug: ixabepilone; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2012
A Safety and Efficacy Study of Farletuzumab in Subjects With Adenocarcinoma of the Lung

Condition: Adenocarcinoma of the Lung
Interventions: Biological: farletuzumab; Other: Placebo; Drug: Platinum Containing Doublet
Sponsors: Morphotek; Morphotek
Recruiting - verified May 2012
Efficacy and Safety Evaluation of EN3348 (Mycobacterial Cell Wall-DNA Complex [MCC]) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent/Refractory Non-muscle Invasive Bladder Cancer

Conditions: Bladder Neoplasm; Intravesical Drug Administration; Neoplasm Recurrence, Local; Transitional Cell, Carcinoma; Carcinoma in Situ; Mycobacterium
Intervention: Biological: EN3348
Sponsors: Endo Pharmaceuticals; Endo Pharmaceuticals
Recruiting - verified February 2012
Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy

Condition: Kidney Cancer
Interventions: Biological: bevacizumab; Drug: everolimus; Other: placebo
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified February 2012
Sulfasalazine in Preventing Acute Diarrhea in Patients With Cancer Who Are Undergoing Pelvic Radiation Therapy

Conditions: Diarrhea; Gastrointestinal Complications; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: sulfasalazine; Other: placebo
Sponsors: National Cancer Institute (NCI); North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified April 2012
Evaluation of SJG-136 for Cisplatin- Refractory /Resistant Epithelial Ovarian

Condition: Ovarian Carcinoma
Intervention: Drug: SJG-136
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; H. Lee Moffitt Cancer Center and Research Institute; National Cancer Institute (NCI)
Recruiting - verified March 2012
Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer

Conditions: Adenocarcinoma of the Gastroesophageal Junction; Esophageal Cancer
Interventions: Biological: trastuzumab; Drug: carboplatin; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Single Agent Ofatumumab Vs. Single Agent Rituximab in Follicular Lymphoma Relapsed After Rituximab-Containing Therapy

Condition: Lymphoma, Follicular
Interventions: Biological: Ofatumumab; Biological: Rituximab
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2012
TRINOVA-1: A Study of AMG 386 or Placebo, in Combination With Weekly Paclitaxel Chemotherapy, as Treatment for Ovarian Cancer, Primary Peritoneal Cancer and Fallopian Tube Cancer

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cancer
Interventions: Drug: AMG 386; Drug: AMG 386 Placebo
Sponsors: Amgen; Amgen
Recruiting - verified May 2012
Risk-Adapted Chemotherapy in Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia

Condition: Leukemia
Interventions: Drug: cyclophosphamide; Drug: cytarabine; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: pegaspargase; Drug: thioguanine; Drug: vincristine sulfate
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Low-dose (12 Gy) TSEBT+Vorinostat Versus Low-dose TSEBT Monotherapy in Mycosis Fungoides

Condition: Cutaneous Lymphoma
Interventions: Procedure: TSEBT; Drug: Vorinostat
Sponsors: Stanford University; Stanford University
Recruiting - verified August 2011
A Study in Second Line Metastatic Colorectal Cancer

Condition: Colorectal Cancer
Interventions: Biological: Ramucirumab; Drug: Irinotecan; Biological: Placebo; Drug: Folinic Acid; Drug: 5-Fluorouracil
Sponsors: Eli Lilly and Company; Eli Lilly and Company; ImClone LLC
Recruiting - verified May 2012
A Study of Chemotherapy and Ramucirumab vs. Chemotherapy Alone in Second Line Non-small Cell Lung Cancer Patients Who Received Prior First Line Platinum Based Chemotherapy

Condition: Non Small Cell Lung Cancer
Interventions: Drug: Docetaxel; Biological: Ramucirumab; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company; ImClone LLC
Recruiting - verified May 2012
Study for Women With Platinum Resistant Ovarian Cancer Evaluating EC145 in Combination With Doxil® (PROCEED)

Condition: Ovarian Cancer
Interventions: Drug: EC145; Drug: Pegylated Liposomal Doxorubicin (PLD/Doxil®/Caelyx®); Drug: placebo; Drug: EC20
Sponsors: Endocyte; Endocyte
Recruiting - verified March 2012
Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy

Conditions: Head and Neck Cancer; Mucositis; Oral Complications of Radiation Therapy; Pain
Interventions: Drug: doxepin hydrochloride; Other: placebo
Sponsors: National Cancer Institute (NCI); North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified February 2012
MLN8237 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia

Conditions: Brain and Central Nervous System Tumors; Childhood Germ Cell Tumor; Kidney Cancer; Leukemia; Liver Cancer; Neuroblastoma; Sarcoma
Interventions: Drug: alisertib; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery

Condition: Colorectal Cancer
Interventions: Drug: celecoxib; Drug: fluorouracil; Drug: leucovorin calcium; Drug: oxaliplatin; Other: placebo
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified February 2012
Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer

Conditions: Adenocarcinoma of the Gastroesophageal Junction; Esophageal Cancer
Interventions: Biological: cixutumumab; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified June 2011
Incidence of Cancer in Women at Increased Genetic Risk of Ovarian Cancer

Conditions: Breast Cancer; Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Other: questionnaire administration; Procedure: evaluation of cancer risk factors; Procedure: quality-of-life assessment; Procedure: study of high risk factors
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Risk-Based Classification System of Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Condition: Leukemia
Interventions: Genetic: DNA ploidy analysis; Genetic: chromosomal translocation analysis; Genetic: cytogenetic analysis; Genetic: fluorescence in situ hybridization; Other: cytology specimen collection procedure; Other: flow cytometry; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer

Condition: Endometrial Cancer
Interventions: Drug: cediranib maleate; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified November 2011
Interactive Cancer Communication System (ICCS) Directed Physical Activity Enhancement for Colon Cancer Survivors

Condition: Colon Cancer
Interventions: Behavioral: Survivorship CHESS; Other: Control
Sponsors: University of Wisconsin, Madison; University of Wisconsin, Madison; University of North Carolina, Chapel Hill; M.D. Anderson Cancer Center; Hartford Hospital
Recruiting - verified November 2011
A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Patients With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib

Condition: Hepatocellular Carcinoma
Interventions: Biological: Placebo; Biological: Ramucirumab DP (IMC-1121B)
Sponsors: ImClone LLC; ImClone LLC
Recruiting - verified February 2012
Chemotherapy Based on Positron Emission Tomography Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma

Condition: Lymphoma
Interventions: Biological: bleomycin sulfate; Drug: ABVD regimen; Drug: BEACOPP regimen; Drug: cyclophosphamide; Drug: dacarbazine; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: prednisone; Drug: procarbazine hydrochloride; Drug: vinblastine sulfate; Drug: vincristine sulfate; Other: laboratory biomarker analysis; Procedure: computed tomography; Radiation: fludeoxyglucose F 18; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified May 2012
Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer

Condition: Breast Cancer
Interventions: Drug: tamoxifen citrate; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2012
Study of Denileukin Diftitox in Patients With Stage IIIC and Stage IV Melanoma

Conditions: Stage IIIC Melanoma; Stage IV Melanoma
Intervention: Drug: Denileukin diftitox
Sponsors: Eisai Inc.; Eisai Inc.; PharmaBio Development Inc.
Recruiting - verified May 2012
LUX-Breast 1: BIBW 2992 (Afatinib) in HER2-positive Metastatic Breast Cancer Patients After One Prior Herceptin Treatment

Condition: Breast Neoplasms
Interventions: Drug: BIBW 2992; Drug: trastuzumab; Drug: vinorelbine; Drug: vinorelbine
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012
Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery

Condition: Kidney Cancer
Interventions: Drug: everolimus; Other: placebo
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2012
Bicalutamide and Goserelin or Leuprolide Acetate With or Without Cixutumumab in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer

Condition: Prostate Cancer
Interventions: Biological: cixutumumab; Drug: bicalutamide; Drug: goserelin acetate; Drug: leuprolide acetate
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified December 2011
A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Patients With Metastatic Breast Cancer (MARIANNE)

Condition: Breast Cancer
Interventions: Drug: trastuzumab emtansine; Drug: pertuzumab; Drug: pertuzumab-placebo; Drug: trastuzumab [Herceptin]; Drug: docetaxel; Drug: paclitaxel
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche; Genentech
Recruiting - verified March 2012
Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer

Condition: Lung Cancer
Interventions: Biological: bevacizumab; Drug: pemetrexed disodium
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2012
Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer

Condition: Breast Cancer
Interventions: Drug: letrozole; Drug: panobinostat; Genetic: RNA analysis; Genetic: microarray analysis; Genetic: reverse transcriptase-polymerase chain reaction; Other: enzyme-linked immunosorbent assay; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry

Condition: Peripheral T-cell Lymphoma
Intervention:
Sponsors: Allos Therapeutics; Allos Therapeutics
Recruiting - verified December 2011
A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer

Condition: Breast Cancer
Interventions: Drug: metformin hydrochloride; Other: placebo
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Radiation Therapy With or Without Chemotherapy in Patients With Stage I or Stage II Cervical Cancer Who Previously Underwent Surgery

Condition: Cervical Cancer
Interventions: Drug: cisplatin; Radiation: external beam radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2012
Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity in Patients With Colon Cancer or Rectal Cancer Receiving Oxaliplatin-Based Combination Chemotherapy

Conditions: Chemotherapeutic Agent Toxicity; Colorectal Cancer; Neuropathy; Neurotoxicity
Interventions: Drug: calcium gluconate; Drug: magnesium sulfate; Other: placebo
Sponsors: National Cancer Institute (NCI); North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer

Conditions: brca1 Mutation Carrier; brca2 Mutation Carrier; Breast Cancer
Interventions: Dietary Supplement: cholecalciferol; Other: placebo
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Younger Patients With Newly Diagnosed Ependymoma

Condition: Brain and Central Nervous System Tumors
Interventions: Drug: cisplatin; Drug: cyclophosphamide; Drug: etoposide; Drug: vincristine sulfate; Other: clinical observation; Radiation: 3-dimensional conformal radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
A Study for Patients With Recurrent or Metastatic Squamous Cell Head and Neck Cancer

Condition: Head and Neck Neoplasms
Interventions: Drug: Pemetrexed; Drug: Cetuximab; Drug: Carboplatin; Drug: Cisplatin
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified October 2011
Paclitaxel, Cisplatin, and Cetuximab Followed By Cetuximab and Intensity-Modulated Radiation Therapy in Treating Patients With HPV-Associated Stage III or Stage IV Cancer of the Oropharynx That Can Be Removed By Surgery

Conditions: Head and Neck Cancer; Precancerous Condition
Interventions: Biological: cetuximab; Radiation: intensity-modulated radiation therapy
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified June 2011
Trial of BIBW 2992 (Afatinib) + Cetuximab in Non-Small Cell Lung Cancer

Condition: Carcinoma, Non-Small-Cell Lung
Intervention: Drug: BIBW 2992 plus cetuximab
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012
Trial of Gemcitabine/Carboplatin With or Without Iniparib (SAR240550) (a PARP1 Inhibitor) in Subjects With Previously Untreated Stage IV Squamous Non-Small-Cell Lung Cancer (NSCLC)

Condition: Squamous Cell Lung Cancer
Interventions: Drug: gemcitabine/carboplatin; Drug: gemcitabine/carboplatin plus Iniparib
Sponsors: Sanofi-Aventis; Sanofi-Aventis; BiPar Sciences
Recruiting - verified March 2012
Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Receiving Chemotherapy

Conditions: Cognitive/Functional Effects; Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Drug: systemic chemotherapy; Other: questionnaire administration; Procedure: assessment of therapy complications; Procedure: cognitive assessment; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified October 2011
Irinotecan Hydrochloride and Cetuximab With or Without Ramucirumab in Treating Patients With Advanced Colorectal Cancer With Progressive Disease After Treatment With Bevacizumab-Containing Chemotherapy

Condition: Colorectal Cancer
Interventions: Biological: cetuximab; Biological: ramucirumab; Drug: irinotecan hydrochloride
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified April 2012
Connect® MM- The Multiple Myeloma Disease Registry

Condition: Multiple Myeloma
Intervention:
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified June 2011
Immunotherapy Study for Surgically Resected Pancreatic Cancer

Condition: Pancreatic Cancer
Interventions: Biological: HyperAcute-Pancreas Immunotherapy; Drug: Gemcitabine; Radiation: 5FU Chemoradiation
Sponsors: NewLink Genetics Corporation; NewLink Genetics Corporation
Recruiting - verified May 2012
Investigate Safety, Pharmacokinetics and Pharmacodynamics of GSK2118436 & GSK1120212

Condition: Cancer
Interventions: Drug: GSK2118436; Drug: GSK1120212
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified December 2011
Study to Assess the Effect of Treatment With Bendamustine in Combination With Rituximab on QT Interval in Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL)

Conditions: Non-Hodgkin's Lymphoma; Mantle Cell Lymphoma
Intervention: Drug: bendamustine and rituximab
Sponsors: Teva Pharmaceutical Industries; Cephalon
Recruiting - verified May 2012
Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)

Condition: Breast Cancer
Interventions: Drug: Placebo; Drug: Denosumab
Sponsors: Amgen; Amgen; Daiichi Sankyo Inc.
Recruiting - verified May 2012
Endometrial Effects of Metformin Action in Women With Polycystic Ovarian Syndrome (PCOS)

Condition: Polycystic Ovarian Syndrome
Interventions: Drug: Endometrin (progesterone 100mg vaginal inserts); Drug: Metformin
Sponsors: Yale University; Yale University; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified February 2012
A Study in Head and Neck Cancer

Condition: Head and Neck Neoplasms
Interventions: Drug: Cetuximab; Drug: Carboplatin; Drug: 5 - Fluorouracil
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified March 2012
Radiation Therapy in Treating Patients With Extensive Stage Small Cell Lung Cancer

Condition: Lung Cancer
Interventions: Radiation: prophylactic cranial irradiation; Radiation: selective external radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified April 2012
Safety Study for Refractory or Relapsed Neuroblastoma With DFMO Alone and in Combination With Etoposide

Condition: Neuroblastoma
Interventions: Drug: DFMO; Drug: Etoposide
Sponsors: Van Andel Research Institute; Giselle Sholler; Cancer Prevention Pharmaceuticals, Inc.; University of Arizona; University of Hawaii; University of Hawaii Cancer Research Center
Recruiting - verified April 2012
Temozolomide, Cixutumumab, and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma

Condition: Sarcoma
Interventions: Biological: cixutumumab; Biological: dactinomycin; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: ifosfamide; Drug: irinotecan hydrochloride; Drug: temozolomide; Drug: vincristine sulfate
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck

Conditions: Ovarian Cancer; Non Small Cell Lung Cancer; Prostate Cancer; Colorectal Cancer; Gastric Cancer; Esophageal Cancer; Cancer of Head and Neck
Interventions: Drug: LY2523355; Drug: pegfilgrastim
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2012
MLN8237 in Adults With Nonhematological Malignancies, Followed by MLN8237 in Lung, Breast, Head and Neck or Gastroesophageal Malignancies

Conditions: Advanced Nonhematological Malignancies; Non-Small Cell Lung Cancer; Small Cell Lung Cancer; Metastatic Breast Cancer; Head and Neck Squamous Cell Carcinoma; Gastroesophageal Adenocarcinoma
Intervention: Drug: MLN8237
Sponsors: Millennium Pharmaceuticals, Inc.; Millennium Pharmaceuticals, Inc.
Recruiting - verified April 2012
Gemcitabine Hydrochloride or Pemetrexed Disodium and Carboplatin With or Without Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer

Condition: Lung Cancer
Interventions: Drug: carboplatin; Drug: celecoxib; Drug: gemcitabine hydrochloride; Drug: pemetrexed disodium; Other: placebo
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified February 2012
Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia

Condition: Leukemia
Interventions: Drug: clofarabine; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: decitabine; Other: clinical observation
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified January 2012
A Study for Patients With Small-Cell Lung Cancer

Condition: Small Cell Lung Cancer
Intervention: Drug: LY2523355
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified February 2012
Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma

Condition: Multiple Myeloma
Interventions: Drug: Panobinostat; Drug: Bortezomib
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012
Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma

Condition: Malignant Melanoma
Interventions: Drug: BMS-936558 (MDX1106-04); Drug: Ipilimumab (BMS-734016); Drug: BMS-936558 (MDX1106-04); Drug: BMS-936558 (MDX1106-04); Drug: BMS-936558 (MDX1106-04); Drug: BMS-936558 (MDX1106-04); Drug: BMS-936558 (MDX1106-04); Drug: Ipilimumab (BMS-734016)
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Medarex; Ono Pharma
Recruiting - verified April 2012
Seneca Valley Virus-001 After Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer

Condition: Lung Cancer
Interventions: Biological: Seneca Valley virus-001; Other: placebo
Sponsors: National Cancer Institute (NCI); North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified January 2012
Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer

Condition: Liver Cancer
Interventions: Drug: doxorubicin hydrochloride; Drug: sorafenib tosylate
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified September 2011
Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery

Condition: Pancreatic Cancer
Interventions: Drug: capecitabine; Drug: erlotinib hydrochloride; Drug: fluorouracil; Drug: gemcitabine hydrochloride; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Rosuvastatin in Treating Patients With Stage I or Stage II Colon Cancer That Was Removed By Surgery

Conditions: Colorectal Cancer; Precancerous Condition
Interventions: Drug: rosuvastatin; Other: placebo
Sponsors: National Cancer Institute (NCI); National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI)
Recruiting - verified February 2012
Evaluating an Interactive Cancer Communication System (ICCS) in Lung Cancer

Condition: Lung Cancer, Stage IIIb or IV
Intervention: Other: CHESS website for lung cancer patient + internet access if needed
Sponsors: University of Wisconsin, Madison; University of Wisconsin, Madison; Harry Gray Cancer Center Hartford Hospial; M.D. Anderson Cancer Center; University of Illinois
Recruiting - verified March 2012
Lisinopril or Carvedilol Phosphate in Reducing Side Effects in Women With HER2-Positive Breast Cancer Receiving Trastuzumab

Conditions: Breast Cancer; Cardiac Toxicity
Interventions: Drug: carvedilol phosphate extended-release capsule; Drug: lisinopril; Other: placebo
Sponsors: National Cancer Institute (NCI); University of South Florida; National Cancer Institute (NCI)
Recruiting - verified February 2012
Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients With Advanced or Recurrent Uterine Leiomyosarcoma

Condition: Sarcoma
Interventions: Biological: bevacizumab; Biological: filgrastim; Biological: pegfilgrastim; Drug: docetaxel; Drug: gemcitabine hydrochloride; Other: placebo
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer

Condition: Breast Cancer
Interventions: Drug: Paclitaxel; Drug: Trastuzumab; Drug: Neratinib; Drug: Trastuzumab (post surgery); Drug: Doxorubicin; Drug: Cyclophosphamide
Sponsors: National Surgical Adjuvant Breast and Bowel Project (NSABP); National Surgical Adjuvant Breast and Bowel Project (NSABP); Wyeth Pharmaceuticals, Inc., a Pfizer Company
Recruiting - verified February 2012
Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer

Conditions: HER2/Neu Over-expressing Locally Advanced Breast Cancer; Metastatic Breast Cancer
Interventions: Drug: everolimus, vinorelbine, trastuzumab; Drug: Placebo + vinorelbine + trastuzumab
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012
Study of Tissue and Blood Samples From Patients With High-Grade Glioma

Condition: Brain and Central Nervous System Tumors
Interventions: Genetic: DNA ploidy analysis; Genetic: fluorescence in situ hybridization; Genetic: microsatellite instability analysis; Genetic: mutation analysis; Genetic: polymerase chain reaction; Other: diagnostic laboratory biomarker analysis; Other: flow cytometry; Other: immunohistochemistry staining method
Sponsors: National Cancer Institute (NCI); North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified February 2012
Collecting and Storing Tissue Samples From Patients With Rare or Cutaneous Non-Hodgkin Lymphoma

Conditions: Lymphoma; Lymphoproliferative Disorder
Interventions: Other: biologic sample preservation procedure; Other: informational intervention
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Liver Cancer

Condition: Liver Cancer
Interventions: Drug: cisplatin; Drug: doxorubicin hydrochloride; Drug: fluorouracil; Drug: irinotecan hydrochloride; Drug: vincristine sulfate; Procedure: liver transplantation; Procedure: therapeutic conventional surgery
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified November 2011
Study is Designed to Assess the Safety and Tolerability of AZD4547 at Increasing Doses in Patients With Advanced Tumours

Conditions: Cancer; Advanced Solid Malignancies
Intervention: Drug: AZD4547
Sponsors: AstraZeneca; AstraZeneca
Recruiting - verified March 2012
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma

Conditions: Brain and Central Nervous System Tumors; Neurotoxicity
Interventions: Drug: temozolomide; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
A Study of YM155 Plus Rituximab in Subjects With Non-Hodgkin's Lymphoma Who Have Received Prior Treatment

Condition: Non-Hodgkin's Lymphoma
Interventions: Drug: YM155; Biological: Rituximab
Sponsors: Astellas Pharma Inc; Astellas Pharma Inc
Recruiting - verified March 2012
Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer

Condition: Endometrial Cancer
Interventions: Biological: bevacizumab; Drug: carboplatin; Drug: ixabepilone; Drug: paclitaxel; Drug: temsirolimus
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified July 2011
Erlotinib With or Without Hydroxychloroquine in Chemo-Naive Advanced NSCLC and (EGFR) Mutations

Condition: Non-small Cell Lung Cancer
Interventions: Drug: Erlotinib; Drug: Hydroxychloroquine
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; Stanford University; Yale University; University of Maryland; Genentech
Recruiting - verified April 2012
Carboplatin, Paclitaxel, and Bevacizumab With or Without Everolimus in Treating Patients With Metastatic Malignant Melanoma

Condition: Melanoma (Skin)
Interventions: Biological: bevacizumab; Drug: carboplatin; Drug: everolimus; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified January 2012
Symptom Management in Patients With Recurrent or Persistent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer; Psychosocial Effects of Cancer and Its Treatment
Interventions: Other: communication intervention; Other: educational intervention; Other: internet-based intervention; Other: questionnaire administration; Other: study of socioeconomic and demographic variables; Procedure: assessment of therapy complications; Procedure: management of therapy complications; Procedure: psychosocial assessment and care; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Study of Lenalidomide to Evaluate Safety and Efficacy in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Condition: Relapsed or Refractory Chronic Lymphocytic Leukemia
Intervention: Drug: lenalidomide
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified February 2012
Radiation Therapy With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer

Condition: Head and Neck Cancer
Interventions: Biological: cetuximab; Radiation: intensity-modulated radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Paclitaxel, Carboplatin, and Bevacizumab With or Without Cixutumumab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer

Condition: Lung Cancer
Interventions: Biological: bevacizumab; Biological: cixutumumab; Drug: carboplatin; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed Persistent or Recurrent Uterine or Ovarian Cancer

Conditions: Ovarian Cancer; Sarcoma
Interventions: Drug: carboplatin; Drug: ifosfamide; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Study of Blood Samples From Newborns With Down Syndrome

Condition: Leukemia
Interventions: Genetic: DNA analysis; Genetic: RNA analysis; Genetic: cytogenetic analysis; Genetic: fluorescence in situ hybridization; Genetic: gene expression analysis; Genetic: microarray analysis; Genetic: mutation analysis; Genetic: polymerase chain reaction; Genetic: polymorphism analysis; Other: flow cytometry; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified December 2011
Study of Patients With Advanced Non-Small Cell Lung Cancer

Condition: Advanced Non-Small Cell Lung Cancer
Interventions: Drug: Pemetrexed; Drug: Carboplatin; Drug: Paclitaxel; Biological: Bevacizumab
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2012
A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1

Condition: Advanced Malignancies
Intervention: Biological: CDX-1401 in combination with Resiquimod and/or Poly-ICLC
Sponsors: Celldex Therapeutics; Celldex Therapeutics
Recruiting - verified November 2011
Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer

Condition: Lung Cancer
Interventions: Biological: bevacizumab; Biological: cetuximab; Drug: carboplatin; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer

Conditions: Bladder Cancer; Prostate Cancer; Transitional Cell Cancer of the Renal Pelvis and Ureter; Urethral Cancer
Interventions: Biological: bevacizumab; Drug: cisplatin; Drug: gemcitabine hydrochloride; Drug: placebo administration
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified August 2011
Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer

Condition: Endometrial Cancer
Interventions: Drug: carboplatin; Drug: cisplatin; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2012
Study of MDX-1203 in Subjects With Advanced/Recurrent Clear Cell Renal Cell Carcinoma (ccRCC) or Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL)

Conditions: Renal Cell Carcinoma; Non-hodgkin's Lymphoma
Intervention: Biological: MDX-1203
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified February 2012
Docetaxel, Oxaliplatin, Capecitabine, Fluorouracil, and Radiation Therapy in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction

Conditions: Adenocarcinoma of the Gastroesophageal Junction; Esophageal Cancer; Gastric Cancer
Interventions: Drug: capecitabine; Drug: docetaxel; Drug: fluorouracil; Drug: oxaliplatin
Sponsors: National Cancer Institute (NCI); North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: bicalutamide; Drug: buserelin; Drug: flutamide; Drug: goserelin acetate; Drug: leuprolide acetate; Drug: triptorelin; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Myelodysplastic Syndromes (MDS) Event Free Survival With Iron Chelation Therapy Study

Condition: Myelodysplastic Syndromes
Interventions: Drug: Deferasirox; Drug: Deferasirox placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified March 2012
An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene

Condition: Carcinoma, Non-Small-Cell Lung
Intervention: Drug: PF-02341066
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012
An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene

Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: PF-02341066; Drug: Pemetrexed; Drug: Docetaxel
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Conditions: Cancer; Cataract; Low Bone Mineral Density; Osteopenia; Osteoporosis; Prostate Cancer
Interventions: Biological: Denosumab; Biological: Placebo
Sponsors: Amgen; Amgen
Recruiting - verified March 2012
Trial of Dasatinib Plus Ixabepilone in 2nd or 3rd Line Metastatic Breast Cancer

Condition: Metastatic Breast Cancer
Interventions: Drug: Dasatinib; Drug: Ixabepilone
Sponsors: Accelerated Community Oncology Research Network; Accelerated Community Oncology Research Network; Bristol-Myers Squibb
Recruiting - verified February 2012
Image-Guided Radiosurgery or Stereotactic Body Radiation Therapy in Treating Patients With Localized Spine Metastasis

Conditions: Metastatic Cancer; Pain
Interventions: Radiation: external beam radiation therapy; Radiation: image-guided radiation therapy; Radiation: radiosurgery; Radiation: stereotactic body radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Collecting and Storing Blood and Brain Tumor Tissue Samples From Children With Brain Tumors

Condition: Brain and Central Nervous System Tumors
Intervention: Other: biologic sample preservation procedure
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Collecting and Storing Tissue, Blood, and Bone Marrow Samples From Patients With Rhabdomyosarcoma or Other Soft Tissue Sarcoma

Conditions: Chordoma; Desmoid Tumor; Sarcoma
Interventions: Genetic: reverse transcriptase-polymerase chain reaction; Other: biologic sample preservation procedure; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
A Study of Paclitaxel/Carboplatin With or Without IMC-3G3 in Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Condition: Non-Small Cell Lung Cancer
Interventions: Biological: IMC-3G3; Drug: Paclitaxel; Drug: carboplatin
Sponsors: ImClone LLC; ImClone LLC
Recruiting - verified February 2012
Optical Tomography With Ultrasound Guidance

Condition: Breast Cancer
Intervention:
Sponsors: University of Connecticut Health Center; University of Connecticut Health Center; National Institute for Biomedical Imaging and Bioengineering (NIBIB); Donaghue Medical Research Foundation
Recruiting - verified June 2011
PAVES: Pegfilgrastim Anti-VEGF Evaluation Study

Conditions: Cancer; Colon Cancer; Colorectal Cancer; Fever; Locally Advanced; Metastatic Colorectal Cancer; Neutropenia; Rectal Cancer
Interventions: Drug: Pegfilgrastim; Drug: Placebo
Sponsors: Amgen; Amgen
Recruiting - verified January 2012
Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer

Conditions: Impotence; Prostatic Neoplasms
Interventions: Drug: Sildenafil therapy plus post-NSRRP HBO2T; Drug: Sildenafil therapy plus sham post-NSRRP HBO2T
Sponsors: Hartford Hospital; Hartford Hospital
Recruiting - verified April 2011
Study Of The Effectiveness & Safety Of Lenalidomide Versus Chlorambucil As First Line Therapy For Elderly Patients With B-Cell CLL (The ORIGIN Trial)

Condition: B-Cell Chronic Lymphocytic Leukemia (B-CLL)
Interventions: Drug: Lenalidomide; Drug: Chlorambucil
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified September 2011
A Prospective Study for the Assessment of Recurrence Risk in Stage II Colon Cancer Patients Using ColoPrint

Condition: Colon Cancer
Intervention:
Sponsors: Agendia; Agendia
Recruiting - verified March 2012
Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma

Condition: Neuroblastoma
Interventions: Genetic: fluorescence in situ hybridization; Genetic: gene expression analysis; Genetic: nucleic acid amplification; Genetic: polymerase chain reaction; Genetic: reverse transcriptase-polymerase chain reaction; Other: cytology specimen collection procedure; Other: flow cytometry; Procedure: biopsy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Tumor Marker YKL-40 in Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing Chemotherapy

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Intervention: Other: diagnostic laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Study of Kidney Tumors in Young Patients

Conditions: Kidney Cancer; Nonneoplastic Condition
Interventions: Genetic: loss of heterozygosity analysis; Genetic: polymerase chain reaction; Genetic: polymorphism analysis; Other: immunohistochemistry staining method; Procedure: computed tomography; Procedure: magnetic resonance imaging
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Collecting Tumor Samples From Patients With Gynecological Tumors

Condition: Cancer
Intervention: Other: biologic sample preservation procedure
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified December 2011
Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer

Conditions: Leukemia; Neoplasm of Uncertain Malignant Potential; Unspecified Childhood Solid Tumor, Protocol Specific
Intervention: Other: cytology specimen collection procedure
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Collecting and Storing Blood, Bone Marrow, and Other Samples From Patients With Acute Leukemia, Chronic Leukemia, or Myelodysplastic Syndromes

Conditions: Leukemia; Lymphoma; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms
Intervention: Other: biologic sample preservation procedure
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified May 2012
Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium

Conditions: Breast Cancer; Hypercalcemia of Malignancy; Colon Cancer; Endocrine Cancer; Head and Neck Cancer; Kidney Cancer; Lung Cancer; Lymphoma; Metastatic Cancer; Multiple Myeloma; Parathyroid Neoplasms; Renal Cancer; Thyroid Cancer; Hodgkin's Lymphoma; Non-Hodgkin's Lymphoma; Non-Small Cell Lung Cancer
Intervention: Drug: denosumab
Sponsors: Amgen; Amgen
Recruiting - verified May 2012
Collecting and Storing Biological Samples From Patients With Ewing Sarcoma

Condition: Sarcoma
Interventions: Other: biologic sample preservation procedure; Other: medical chart review
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Collecting and Storing Samples of Blood and Tumor Tissue From Patients With Osteosarcoma

Condition: Sarcoma
Intervention: Other: biologic sample preservation procedure
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Studying Biomarkers in Diagnosing Cervical Lesions in Patients With Abnormal Cervical Cells

Conditions: Cervical Cancer; Precancerous Condition
Interventions: Genetic: DNA analysis; Genetic: gene expression analysis; Other: diagnostic laboratory biomarker analysis; Other: immunohistochemistry staining method; Procedure: cone biopsy; Procedure: endocervical curettage; Procedure: histopathologic examination; Procedure: loop electrosurgical excision procedure
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified December 2011
Collecting and Storing Samples of Bone Marrow and Blood From Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma

Conditions: Leukemia; Lymphoma
Intervention: Other: biologic sample preservation procedure
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Collecting and Storing Biological Samples From Young Patients With Hodgkin's Lymphoma

Condition: Lymphoma
Intervention: Other: biologic sample preservation procedure
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
A Study of Ixabepilone as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer

Condition: Endometrial Cancer
Interventions: Drug: Ixabepilone; Drug: Doxorubicin; Drug: Paclitaxel
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified February 2012
Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Conditions: Breast Cancer; Lung Cancer; Metastatic Cancer; Multiple Myeloma and Plasma Cell Neoplasm; Prostate Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Intervention: Procedure: assessment of therapy complications
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed By Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery

Condition: Breast Cancer
Interventions: Biological: bevacizumab; Drug: carboplatin; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified May 2012
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia

Condition: Leukemia
Interventions: Drug: arsenic trioxide; Drug: cytarabine; Drug: idarubicin; Drug: mercaptopurine; Drug: methotrexate; Drug: mitoxantrone hydrochloride; Drug: tretinoin; Genetic: cytogenetic analysis; Genetic: polymerase chain reaction; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy

Conditions: Non-Small Cell Lung Cancer; Anemia; Cancer; Lung Cancer
Interventions: Drug: darbepoetin alfa 500 mcg Q3W; Drug: placebo
Sponsors: Amgen; Amgen
Recruiting - verified May 2012
Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Doxorubicin, Cyclophosphamide, and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer

Condition: Breast Cancer
Interventions: Biological: bevacizumab; Biological: pegfilgrastim; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: paclitaxel albumin-stabilized nanoparticle formulation
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
An Open-Label Study of Trastuzumab Emtansine (T-DM1) vs Capecitabine+Lapatinib in Patients With HER2-Positive Locally Advanced or Metastatic Breast Cancer (EMILIA)

Condition: Breast Cancer
Interventions: Drug: trastuzumab emtansine; Drug: lapatinib; Drug: capecitabine [Xeloda]
Sponsors: Genentech; Genentech
Recruiting - verified April 2012
Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma

Condition: Lymphoma
Interventions: Biological: bleomycin sulfate; Biological: filgrastim; Drug: ABVD regimen; Drug: BEACOPP regimen; Drug: cyclophosphamide; Drug: dacarbazine; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: prednisone; Drug: procarbazine hydrochloride; Drug: vinblastine sulfate; Drug: vincristine sulfate; Radiation: fludeoxyglucose F 18
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified January 2012
Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer

Conditions: Endometrial Cancer; Fatigue; Neurotoxicity
Interventions: Drug: carboplatin; Drug: paclitaxel; Radiation: brachytherapy; Radiation: intensity-modulated radiation therapy; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2012
Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer

Condition: Cervical Cancer
Interventions: Biological: bevacizumab; Drug: cisplatin; Drug: paclitaxel; Drug: topotecan hydrochloride
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified December 2011
Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy

Condition: Diffuse Large B-cell Lymphoma
Interventions: Drug: RAD001; Drug: Placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012
Neuropsychological and Behavioral Testing in Young Patients With Medulloblastoma or Supratentorial Primitive Neuroectodermal Tumor (PNET)

Conditions: Brain and Central Nervous System Tumors; Chemotherapeutic Agent Toxicity; Cognitive/Functional Effects; Neurotoxicity; Psychosocial Effects of Cancer and Its Treatment; Radiation Toxicity; Therapy-related Toxicity
Interventions: Other: questionnaire administration; Procedure: cognitive assessment; Procedure: psychosocial assessment and care; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy

Condition: Breast Cancer
Interventions: Biological: trastuzumab; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI)
Recruiting - verified April 2012
A Study to Evaluate the Efficacy and Safety of Lenalidomide as Maintenance Therapy for Patients With B-Cell CLL Following Second Line Therapy (THE CONTINUUM TRIAL)

Condition: B-cell Chronic Lymphocytic Leukemia
Interventions: Drug: Lenalidomide; Drug: Placebo
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified May 2012
Stereotactic Body Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer

Condition: Lung Cancer
Intervention: Radiation: stereotactic body radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Compromised Microcirculation in Women With Polycystic Ovary Syndrome

Condition: Polycystic Ovary Syndrome
Interventions: Drug: ganirelix acetate; Drug: methyl testosterone
Sponsors: Yale University; Yale University
Recruiting - verified August 2011
Airway Epithelium Gene Expression: AEGIS II

Condition: Lung Cancer
Intervention: Device: Biomarker (not used as an intervention)
Sponsors: Allegro Diagnostics, Corp.; Allegro Diagnostics, Corp.; University of Pennsylvania; Columbia University; Temple University; Indiana University; University of Alabama at Birmingham; University of Missouri-Columbia; Louisiana State University Health Sciences Center in New Orleans; University of Wisconsin, Madison; Medical University of South Carolina; National Jewish Health; Overlake Hospital Bellevue WA; Pulmonary and Allergy Associates of New Jersey; Pulmonary Associates of Arizona; William Jennings Bryan Dorn VA Medical Center; Virginia Commonwealth University; Jamaica Hospital Medical Center; North Florida/South Georgia Veterans Health System; Steward St. Elizabeth; University of California, Davis; Yale University Medical Center; The Cleveland Clinic; Johns Hopkins University
Recruiting - verified May 2012
Safety and Exploratory Efficacy of Kanglaite Injection in Pancreatic Cancer

Condition: Pancreatic Cancer
Interventions: Drug: Kanglaite Injection plus gemcitabine; Drug: Gemcitabine
Sponsors: KangLaiTe USA; KangLaiTe USA
Recruiting - verified January 2012
A Phase 1b Study of MDX-1106 in Subjects With Advanced or Recurrent Malignancies

Conditions: Metastatic Castration-resistant Prostrate Cancer (mCRPC); Renal Cell Carcinoma (RCC); Metastatic Melanoma (MEL); Non-small Cell Lung Cancer (NSCLC)
Interventions: Biological: BMS-936558 (MDX-1106); Biological: BMS-936558 (MDX-1106); Biological: BMS-936558 (MDX-1106); Biological: BMS-936558 (MDX-1106); Biological: BMS-936558 (MDX-1106)
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Ono Pharmaceutical Company, Ltd.
Recruiting - verified October 2011
Cryoablation Therapy in Treating Patients With Invasive Ductal Breast Cancer

Condition: Breast Cancer
Interventions: Procedure: cryosurgery; Procedure: therapeutic conventional surgery
Sponsors: National Cancer Institute (NCI); American College of Surgeons; National Cancer Institute (NCI)
Recruiting - verified May 2012
Study of Adding AMG 479 to First Line Chemotherapy in Patients With Optimally Debulked Epithelial Ovarian Cancer

Condition: Ovarian Neoplasms
Interventions: Drug: AMG 479; Drug: AMG 479 Placebo
Sponsors: Cancer International Research Group; Cancer International Research Group
Recruiting - verified March 2012
Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy

Conditions: Brain and Central Nervous System Tumors; Childhood Germ Cell Tumor; Extragonadal Germ Cell Tumor; Liver Cancer; Neuroblastoma; Ototoxicity; Ovarian Cancer; Sarcoma
Interventions: Drug: sodium thiosulfate; Procedure: examination
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Chemotherapy and Radiation in Treating Patients With Stage 3 Non-Small Cell Lung Cancer

Condition: Non Small Cell Lung Cancer
Interventions: Drug: Pemetrexed; Drug: Cisplatin; Drug: Etoposide; Drug: Cisplatin; Drug: Vinorelbine; Drug: Paclitaxel; Drug: Carboplatin; Radiation: Thoracic Radiation Therapy (TRT); Radiation: Thoracic Radiation Therapy (TRT)
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2012
ChemoFx® PRO - A Post-Market Data Collection Study

Conditions: Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Cancer; Uterine Neoplasms; Endometrial Cancer; Vaginal Cancer; Vulvar Cancer; Cervical Cancer; Lung Cancer; Carcinoid Tumor of Lung; Sarcoma of Lung; Mesothelioma; Colorectal Cancer
Intervention:
Sponsors: Precision Therapeutics; Precision Therapeutics
Recruiting - verified June 2011
Paclitaxel, Cisplatin, and Radiation Therapy With or Without Cetuximab in Treating Patients With Locally Advanced Esophageal Cancer

Condition: Esophageal Cancer
Interventions: Biological: cetuximab; Drug: cisplatin; Drug: paclitaxel; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Combination Chemotherapy, Radiation Therapy, and an Autologous Peripheral Blood Stem Cell Transplant in Treating Young Patients With Atypical Teratoid/Rhabdoid Tumor of the Central Nervous System

Condition: Brain and Central Nervous System Tumors
Interventions: Biological: filgrastim; Drug: carboplatin; Drug: cisplatin; Drug: cyclophosphamide; Drug: etoposide; Drug: etoposide phosphate; Drug: methotrexate; Drug: thiotepa; Drug: vincristine sulfate; Genetic: mutation analysis; Other: immunohistochemistry staining method; Procedure: autologous hematopoietic stem cell transplantation; Procedure: peripheral blood stem cell transplantation; Radiation: 3-dimensional conformal radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma

Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: bortezomib; Drug: dexamethasone; Drug: lenalidomide
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified June 2011
Sorafenib Long Term Extension Program (STEP)

Condition: Neoplasms
Intervention: Drug: Sorafenib (Nexavar, BAY43-9006)
Sponsors: Bayer; Bayer; ICON Clinical Research
Recruiting - verified May 2012
A Phase I/II Study of BEZ235 in Patients With Advanced Solid Malignancies Enriched by Patients With Advanced Breast Cancer

Conditions: Breast Cancer,; Advanced Solid Tumors,; Cowden Syndrome
Intervention: Drug: BEZ235
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified November 2011
Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma

Conditions: Neuroblastoma; Medulloblastoma
Interventions: Drug: Nifurtimox; Drug: Cyclophosphamide; Drug: Topotecan
Sponsors: Van Andel Research Institute; Giselle Sholler; Bayer
Recruiting - verified April 2012
Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

Condition: Head and Neck Cancer
Interventions: Biological: bevacizumab; Drug: carboplatin; Drug: cisplatin; Drug: docetaxel; Drug: fluorouracil
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2012
Efficacy Study of Oral Sapacitabine to Treat Acute Myeloid Leukemia in Elderly Patients

Condition: Acute Myeloid Leukemia
Interventions: Drug: sapacitabine; Drug: sapacitabine; Drug: sapacitabine; Drug: sapacitabine; Drug: sapacitabine; Drug: sapacitabine; Drug: sapacitabine; Drug: Sapacitabine; Drug: sapacitabine
Sponsors: Cyclacel Pharmaceuticals, Inc.; Cyclacel Pharmaceuticals, Inc.
Recruiting - verified November 2011
Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising PSA After Surgery for Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: bicalutamide; Drug: flutamide; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI); Cancer and Leukemia Group B
Recruiting - verified May 2012
Octreotide and Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor

Condition: Neuroendocrine Carcinoma
Interventions: Biological: bevacizumab; Biological: recombinant interferon alfa-2b; Drug: octreotide acetate
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified January 2012
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Condition: Leukemia
Interventions: Drug: cyclophosphamide; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: mercaptopurine; Drug: methotrexate; Drug: pegaspargase; Drug: thioguanine; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI); Eastern Cooperative Oncology Group; Southwest Oncology Group
Recruiting - verified May 2012
Combination Chemotherapy With or Without Lestaurtinib in Treating Infants With Newly Diagnosed Acute Lymphoblastic Leukemia

Condition: Leukemia
Interventions: Drug: asparaginase; Drug: cyclophosphamide; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: dexamethasone; Drug: etoposide; Drug: lestaurtinib; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: methylprednisolone; Drug: pegaspargase; Drug: prednisone; Drug: therapeutic hydrocortisone; Drug: vincristine sulfate
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Combination Chemotherapy, Autologous Stem Cell Transplant, and/or Radiation Therapy in Treating Young Patients With Extraocular Retinoblastoma

Condition: Retinoblastoma
Interventions: Biological: filgrastim; Drug: carboplatin; Drug: cisplatin; Drug: cyclophosphamide; Drug: etoposide; Drug: thiotepa; Drug: vincristine sulfate; Procedure: autologous bone marrow transplantation; Procedure: autologous hematopoietic stem cell transplantation; Procedure: peripheral blood stem cell transplantation; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia

Condition: Leukemia
Interventions: Drug: arsenic trioxide; Drug: gemtuzumab ozogamicin; Drug: mercaptopurine; Drug: methotrexate; Drug: tretinoin
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified November 2011
Comparison of Different Types of Surgery in Treating Patients With Stage IA Non-Small Cell Lung Cancer

Condition: Lung Cancer
Interventions: Procedure: therapeutic thoracoscopy; Procedure: videothoracoscopy
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI); Radiation Therapy Oncology Group; American College of Surgeons; Southwest Oncology Group
Recruiting - verified April 2012
Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer

Condition: Endometrial Cancer
Interventions: Drug: cisplatin; Radiation: brachytherapy; Radiation: external beam radiation therapy
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Assessment Tool for Older Patients With Cancer

Conditions: Cognitive/Functional Effects; Psychosocial Effects of Cancer and Its Treatment; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Other: questionnaire administration; Procedure: cognitive assessment; Procedure: psychosocial assessment and care
Sponsors: City of Hope Medical Center; City of Hope Medical Center; National Cancer Institute (NCI)
Recruiting - verified March 2012
Assessing Ear Damage in Young Cancer Patients Treated With Cisplatin

Conditions: Ototoxicity; Unspecified Childhood Solid Tumor, Protocol Specific
Intervention: Procedure: management of therapy complications
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: docetaxel; Drug: goserelin acetate; Drug: leuprolide acetate; Procedure: conventional surgery
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI); Eastern Cooperative Oncology Group; NCIC Clinical Trials Group
Recruiting - verified September 2011
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma

Conditions: Leukemia; Lymphoma
Interventions: Drug: cyclophosphamide; Drug: cytarabine; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: nelarabine; Drug: pegaspargase; Drug: prednisone; Drug: thioguanine; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma or Supratentorial Primitive Neuroectodermal Tumor

Condition: Brain and Central Nervous System Tumors
Interventions: Biological: filgrastim; Drug: carboplatin; Drug: cisplatin; Drug: cyclophosphamide; Drug: isotretinoin; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms Tumor

Conditions: Kidney Cancer; Metastatic Cancer
Interventions: Biological: dactinomycin; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: vincristine sulfate; Procedure: therapeutic conventional surgery; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified January 2012
Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia

Condition: Leukemia
Interventions: Biological: filgrastim; Drug: asparaginase; Drug: cyclophosphamide; Drug: cytarabine; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: etoposide phosphate; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: pegaspargase; Drug: prednisone; Drug: therapeutic hydrocortisone; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2012
Education With or Without Exercise and Counseling in Preventing Lymphedema in Women With Stage I, Stage II, or Stage III Breast Cancer Who Are Undergoing Axillary Lymph Node Dissection

Conditions: Breast Cancer; Lymphedema; Perioperative/Postoperative Complications
Interventions: Behavioral: exercise intervention; Other: educational intervention; Procedure: assessment of therapy complications; Procedure: complementary or alternative medicine procedure; Procedure: management of therapy complications; Procedure: quality-of-life assessment; Procedure: therapeutic conventional surgery
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified May 2012
EAP (Expanded Access Protocol) Of Lapatinib Combined With Capecitabine In Metastatic Breast Cancer

Condition: Neoplasms, Breast
Intervention: Drug: lapatinib + capecitabine
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2012
Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma

Condition: Brain and Central Nervous System Tumors
Interventions: Drug: carboplatin; Drug: cisplatin; Drug: cyclophosphamide; Drug: etoposide; Drug: leucovorin calcium; Drug: methotrexate; Drug: thiotepa; Drug: vincristine sulfate
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2011
Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-Small Lung Cancer That Was Removed By Surgery

Condition: Lung Cancer
Interventions: Biological: bevacizumab; Drug: cisplatin; Drug: docetaxel; Drug: gemcitabine hydrochloride; Drug: pemetrexed disodium; Drug: vinorelbine tartrate
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI); Southwest Oncology Group; Cancer and Leukemia Group B; NCIC Clinical Trials Group; North Central Cancer Treatment Group
Recruiting - verified February 2012
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

Condition: Breast Cancer
Intervention: Drug: Zometa® (zoledronic acid)
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012
Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: antiandrogen therapy; Drug: docetaxel
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2012
Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial)

Condition: Breast Cancer
Interventions: Drug: anastrozole; Drug: chemotherapy; Drug: exemestane; Drug: letrozole; Drug: tamoxifen citrate
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI); Southwest Oncology Group; Cancer and Leukemia Group B; American College of Surgeons; North Central Cancer Treatment Group; NCIC Clinical Trials Group; National Surgical Adjuvant Breast and Bowel Project (NSABP)
Recruiting - verified July 2011
Cisplatin-Based Chemotherapy and/or Surgery in Treating Young Patients With Adrenocortical Tumor

Condition: Adrenocortical Carcinoma
Interventions: Biological: filgrastim; Biological: pegfilgrastim; Drug: cisplatin; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: mitotane; Procedure: conventional surgery
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified July 2011
Chemotherapy After Prostatectomy (CAP) For High Risk Prostate Carcinoma

Condition: Prostate Cancer
Interventions: Drug: Docetaxel; Drug: Prednisone
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs; Sanofi-Aventis
Recruiting - verified September 2011
Combination Chemotherapy, PEG-Interferon Alfa-2b, and Surgery in Treating Patients With Osteosarcoma

Condition: Sarcoma
Interventions: Biological: PEG-interferon alfa-2b; Drug: cisplatin; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: ifosfamide; Drug: methotrexate
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI); University College London Hospitals
Recruiting - verified June 2011
Radiation Therapy in Treating Women Who Have Undergone Surgery For Ductal Carcinoma In Situ or Stage I or Stage II Breast Cancer

Condition: Breast Cancer
Interventions: Radiation: 3-dimensional conformal accelerated partial breast irradiation; Radiation: brachytherapy; Radiation: whole breast irradiation
Sponsors: National Cancer Institute (NCI); National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI); Radiation Therapy Oncology Group; Southwest Oncology Group
Recruiting - verified May 2012
Isotretinoin With or Without Monoclonal Antibody, Interleukin-2, and Sargramostim Following Stem Cell Transplantation in Treating Patients With Neuroblastoma

Condition: Neuroblastoma
Interventions: Biological: aldesleukin; Biological: monoclonal antibody Ch14.18; Biological: sargramostim; Drug: isotretinoin
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Paclitaxel in Treating Patients With Ovarian Stromal Cancer

Condition: Ovarian Cancer
Intervention: Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012